Richard Nolan Townsend - Nov 2, 2023 Form 3 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Jenny Robertson, Attorney-in-Fact
Stock symbol
LXEO
Transactions as of
Nov 2, 2023
Transactions value $
$0
Form type
3
Date filed
11/2/2023, 09:42 PM
Next filing
Jan 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LXEO Common Stock 127K Nov 2, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LXEO Employee Stock Option (right to buy) Nov 2, 2023 Common Stock 154K $2.33 Direct F1
holding LXEO Employee Stock Option (right to buy) Nov 2, 2023 Common Stock 519K $4.87 Direct F2
holding LXEO Employee Stock Option (right to buy) Nov 2, 2023 Common Stock 106K $11.02 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2 25% of the shares underlying the option vested on August 11, 2022, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3 25% of the shares underlying the option shall vest on August 22, 2024, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney